Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$14.07 - $17.3 $1.52 Million - $1.87 Million
-108,233 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$16.62 - $18.94 $631,792 - $719,985
-38,014 Reduced 25.99%
108,233 $1.88 Million
Q1 2021

May 12, 2021

BUY
$15.15 - $19.78 $2.22 Million - $2.89 Million
146,247 New
146,247 $2.53 Million
Q2 2020

Aug 14, 2020

SELL
$18.24 - $21.45 $1.9 Million - $2.23 Million
-103,950 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$16.28 - $25.63 $81,741 - $128,688
-5,021 Reduced 4.61%
103,950 $2.09 Million
Q4 2019

Feb 14, 2020

SELL
$19.57 - $23.52 $7.05 Million - $8.48 Million
-360,352 Reduced 76.78%
108,971 $2.54 Million
Q3 2019

Nov 13, 2019

SELL
$19.85 - $22.76 $1.23 Million - $1.41 Million
-61,959 Reduced 11.66%
469,323 $9.41 Million
Q2 2019

Aug 13, 2019

SELL
$17.59 - $21.1 $95,337 - $114,362
-5,420 Reduced 1.01%
531,282 $11.2 Million
Q1 2019

May 13, 2019

SELL
$18.01 - $20.11 $148,996 - $166,370
-8,273 Reduced 1.52%
536,702 $10.8 Million
Q4 2018

Feb 12, 2019

BUY
$17.44 - $21.53 $394,178 - $486,621
22,602 Added 4.33%
544,975 $10 Million
Q3 2018

Nov 14, 2018

BUY
$19.97 - $21.96 $125,870 - $138,413
6,303 Added 1.22%
522,373 $11.2 Million
Q2 2018

Sep 18, 2018

SELL
$20.16 - $24.68 $344,776 - $422,077
-17,102 Reduced 3.21%
516,070 $11.1 Million
Q2 2018

Aug 14, 2018

BUY
$20.16 - $24.68 $2.38 Million - $2.91 Million
117,871 Added 28.38%
533,172 $11.5 Million
Q1 2018

May 09, 2018

BUY
$20.31 - $24.95 $227,370 - $279,315
11,195 Added 2.77%
415,301 $8.8 Million
Q4 2017

Feb 14, 2018

SELL
$20.99 - $23.89 $1.74 Million - $1.98 Million
-82,801 Reduced 17.01%
404,106 $9.26 Million
Q3 2017

Nov 13, 2017

BUY
$20.07 - $21.89 $9.77 Million - $10.7 Million
486,907
486,907 $10.7 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.33B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.